Toggle Side Panel
Close search

Long-acting insulin shake-up

This update guides GPs through insulin detemir’s phase-out, the basal insulin alternatives, and the practical steps to help patients through the change.

This article has been allocated 0.5 EA by the RACGP and ACRRM for the 2026-2028 triennium.

You can self-report this CPD/PDP activity by logging it online with the RACGP and ACRRM. Click on the link for RACGP Quick Log or go to your ACRRM page.

Need to know

For more than two decades, insulin detemir (Levemir) has been a cornerstone of basal insulin therapy for people living with type 1 diabetes (T1D). Its predictable pharmacology and flexible twice-daily dosing profile have made it a popular option for individuals using multiple daily injections.1

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .